M&A Deal Summary |
|
---|---|
Date | 2015-02-22 |
Target | Salix Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Bausch Health |
Deal Type | Add-on Acquisition |
Deal Value | 14.5B USD |
Advisor(s) | Centerview Partners J.P. Morgan Securities (Financial) Cadwalader, Wickersham & Taft (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Life Science |
Employees | 20,270 |
Revenue | 8.8B USD (2023) |
Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.
DEAL STATS | # |
---|---|
Overall | 28 of 35 |
Sector (Life Science) | 17 of 21 |
Type (Add-on Acquisition) | 20 of 25 |
State (North Carolina) | 1 of 2 |
Country (United States) | 16 of 22 |
Year (2015) | 1 of 6 |
Size (of disclosed) | 1 of 27 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-11-17 |
NicOx
Warren Township, New Jersey, United States NicOx, Inc. distributes nitric oxide (NO)-donating drug. |
Buy | $20M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-02-23 |
Dendreon Pharmaceuticals
Seattle, Washington, United States Dendreon Pharmaceuticals, Inc. is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. |
Buy | $400M |